Carl Johan Fredin has an MBA degree from Stockholm University. He has almost 30 years' experience from leading commercial positions as well as the CEO role in the life science sector and especially in the pharmaceutical industry. Currently, he is Country Director, Public Care, at Doro AB. His career besides Doro AB includes GlaxoSmithKline AB, a number of positions within Janssen-Cilag AB as well as Global Health Partner AB, Aleris AB and Mundipharma Sweden AB.

In his various roles, Carl Johan has been responsible for and worked with; start-up of new business units, establishment of international distribution channels, launch of new products in international markets, pricing and reimbursement negotiations with authorities, improvement of sales methods and launch of digital marketing tools.

"I am very pleased and proud to be entrusted with the future development of AcuCort. It is a privilege to be leading the work with the goal to bring the company's first product ISICORT® to the global market," says AcuCort's incoming CEO Carl Johan Fredin.

"I am very pleased with the recruitment of Carl Johan Fredin as CEO of AcuCort. Carl Johan has worked with commercialization matters in international life science companies for many years. His skills and experiences match very well with AcuCort's needs, given a possible market approval in Sweden of the company's drug candidate ISICORT® during the second half of 2020. I also want to take this opportunity and thank Ann Gidner for her very strong contributions to AcuCort," says Ebba Fåhraeus, Chairman of the Board of AcuCort AB.

For further information, please contact
Ebba Fåhraeus, Chairman of the Board, AcuCort AB
Phone: +46 (0)73 400 04 33
Email: ebba@lysaeus.com

About AcuCort AB (publ)

AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance - dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company's assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at www.acucort.com